The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH.
benign prostatic hyperplasia
embolisation
medical therapy
urinary tract symptoms
urodynamics
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential first-line therapy for obstructive benign prostatic hyperplasia (BPH) in treatment-naïve patients in the 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE). A total of 39 men with enlarged prostates, moderate-severe lower urinary tract symptoms (LUTS) and obstructed/equivocal urodynamic studies (UDS), and who had no prior treatment for BPH, were randomised to receive either combined medical therapy with tamsulosin and dutasteride (medication) or PAE. Follow-up UDS, International Prostate Symptom Score (IPSS), uroflowmetry and ultrasound were performed at short- to medium-term intervals following interventions and compared to baseline. The medication and PAE treatment groups had similar baseline characteristics, including prostate volumes (87.8 and 85.4 mL respectively), maximum urinary flow rate (Q Prostate artery embolisation was more effective than combined medical therapy at reducing urinary obstruction, decreasing prostate volume and improving LUTS in patients with BPH who had not previously been treated. This is the first randomised control study to compare PAE and combined medical therapy in exclusively treatment-naïve patients and raises the potential of PAE as an alternative early treatment option for BPH. Further randomised comparative trials are planned to further validate the role of PAE in mitigating obstructive BPH.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 BJU International.
Références
Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010; 5: 212–218
Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int 2021; 127: 722–728
Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. The long‐term outcome of medical therapy for BPH. Eur Urol 2007; 51: 1522–1533
Pisco JM, Bilhim T, Pinheiro LC et al. Medium‐ and long‐term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 2016; 27: 1115–1122
Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long‐term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single‐centre retrospective study in 1072 patients over a 10‐year period. Cardiovasc Intervent Radiol 2022; 45: 1324–1336
Franco JV, Jung JH, Imamura M, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis. Cochrane Database Syst Rev 2021; (7): CD013656
Insausti I, Sáez de Ocáriz A, Galbete A, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2020; 31: 882–890
Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic‐controlled analysis. Cardiovasc Intervent Radiol 2016; 39: 44–52
Gao YA, Huang Y, Zhang R, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate—a prospective, randomized, and controlled clinical trial. Radiology 2014; 270: 920–928
Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non‐inferiority trial. BMJ 2018; 361: k2338
Sapoval M, Thiounn N, Descazeaud A, et al. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open‐label, phase 3, superiority trial. Lancet Reg Health Eur 2023; 31: 100672
Brown N, Walker D, McBean R, et al. Prostate artery embolisation assessment of safety and feasibilitY (P‐EASY): a potential alternative to long‐term medical therapy for benign prostate hyperplasia. BJU Int 2018; 122(Suppl 5): 27–34
Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 1999; 84: 14–15
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016; 43: 289–297
Cindolo L, Pirozzi L, Sountoulides P, et al. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)‐associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol 2015; 15: 96
Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‐year results from the CombAT study. Eur Urol 2010; 57: 123–131
Bilhim T, McWilliams JP, Bagla S. Updated American urological association guidelines for the management of benign prostatic hyperplasia: prostatic artery embolization made it into the guidelines! Cardiovasc Intervent Radiol 2023; 47: 150–153
Carnevale FC, Moreira AM, de Assis AM, et al. Prostatic artery embolization for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: 10 years' experience. Radiology 2020; 296: 444–451
Bagla S, Smirniotopoulos JB, Orlando JC, van Breda A, Vadlamudi V. Comparative analysis of prostate volume as a predictor of outcome in prostate artery embolization. J Vasc Interv Radiol 2015; 26: 1832–1838
Wang M, Guo L, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium‐ and large‐volume prostates. BJU Int 2016; 117: 155–164
Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54: 419–426
Verhovsky G, Baberashvili I, Rappaport YH, et al. Bladder oversensitivity is associated with bladder outlet obstruction in men. J Pers Med 2022; 12: 1675
Naidu SG, Narayanan H, Saini G, et al. Prostate artery embolization‐review of indications, patient selection, techniques and results. J Clin Med 2021; 10: 5139
Ray AF, Powell J, Speakman MJ, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity‐matched comparison with transurethral resection of the prostate (the UK‐ROPE study). BJU Int 2018; 122: 270–282
Zumstein V, Binder J, Güsewell S, et al. Radiation exposure during prostatic artery embolisation: a systematic review and calculation of associated risks. Eur Urol Focus 2021; 7: 608–611
Salmivalli A, Ettala O, Boström PJ, Kytö V. Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World J Urol 2022; 40: 1785–1791
Michel MC, Bressel HU, Goepel M, Rübben H. A 6‐month large‐scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001; 51: 609–614